In particular, the main finding of our work dealing with PAR1 in our prostatitis model was that the PAR1-activating peptide, TFLLR-NH2, could cause both a PAR1-dependent and a PAR1-independent anti-inflammatory effect. This evidence concerns the gene F2R and urogenital neoplasm.